I just want to be a quiet scholar

Chapter 495 The fate of science students
"Old Qi, sit down." Shen Qi poured Director Qi a glass of water.

"It's like this. Your chemical project C01B, which is a benzazepine compound mentioned in the paper published on JACS, has a pharmaceutical company that wants to buy your patent." Director Qi is indeed the center's God of Wealth, he said again: "The pharmaceutical company may not dare to directly look for someone as big as you, so they found me."

"No problem, we can transfer the C01B patent, who is the buyer?" Shen Qi asked.

Director Qi said: "The buyer is Green Mountain Pharmaceuticals, which is a subsidiary of Pfizer in China, a US-funded enterprise."

Shen Qi said "oh", "Pfizer's subsidiary is interesting."

Director Qi, who is proficient in law and business operations, said: "I have roughly learned some information. It is said that your C01B is similar to Pfizer's smoking cessation drug, Jiebishi, which was launched in 97. The administrative protection of Jiebishi in my country has expired. That is to say, the patent of this smoking cessation drug has expired. When I was studying in the United States, I studied Pfizer’s operation cases. In the past 20 years, Pfizer has invested a lot of human, material and financial resources in acquisitions.”

The current situation of China Chemical Pharmaceuticals is that once the patents of the marketed patented drugs expire, a large number of generic drugs will emerge.As a result, generic drugs account for more than 90% of China's chemical drug market.

There are advantages and disadvantages. Generic drugs that are almost as effective as the original drugs are cheaper and affordable by ordinary people.

But from the perspective of the long-term development of China's pharmaceutical industry, the disadvantages outweigh the advantages.

Most of China's pharmaceutical companies blindly imitate, resulting in very weak core R&D capabilities and almost losing their ability to innovate.

The pharmaceutical industry is a technology-led industry, and pharmaceutical companies without technological innovation capabilities will not be able to grow bigger and stronger, or even survive.

There are too many generic drugs of the same type, and pharmaceutical companies start to fight price wars.

Many small and medium-sized pharmaceutical companies in China specialize in the production of generic drugs. In the fierce competition and even chaotic price wars, most small and medium-sized pharmaceutical companies have been losing money all year round, and have closed down after losing money, or have been acquired by large pharmaceutical groups.

Another big market for generic drugs is India. A pharmaceutical company in India, Aurobindo, specializes in imitating Pfizer’s patented drugs. The quality of the imitated drugs is so high that it is even approved by the FDA.

The Indian pharmaceutical company has imitated more than 100 patented drugs of Pfizer, of which 39 generic drugs have obtained the right to operate in the US market.

The United States advocates global trade, fair competition, and opposition to monopoly. At least the US government is fair and just to Indian companies.

The drug patent has expired, people have the right to imitate it, and Pfizer can't fight a lawsuit.

In the case studied by Director Qi, Pfizer changed its operating model. Since it was unable to crack down on counterfeit factories, Pfizer acquired Aurobindo, an Indian pharmaceutical company that had devoted its life to imitating them.

At the same time, Greenstone Pharmaceuticals, a wholly-owned subsidiary of Pfizer, purchased a large number of generic drugs after the patent expired globally.

The current operating model of the wealthy pharmaceutical giant Pfizer is to maintain the core competitiveness of independent research and development of new drugs, and simultaneously acquire generic drug companies and generic drugs.

Green Mountain Pharmaceuticals, a subsidiary of Pfizer in China, is responsible for the business that is similar to the Green Stone Company they established in the United States, just three words: buy, buy, buy.

Shen Qi said: "So in Pfizer's view, our C01B imitated their Jiebishi?"

Director Qi explained: "The patent law for drugs is very complicated, and it is difficult to explain in one word. Simply put, the same drug can also apply for different patents due to different preparation methods, which belong to technical process patents."

During this period of time, Shen Qi has also learned the rules of the game in the pharmaceutical industry. There is an experienced person in his family who is his doctor mother.

Since the middle of the 20th century, the research and development of chemical drugs has benefited from the development of chemical science and made great strides.Some new compounds were quickly identified in the laboratory and applied to clinical research.

After decades of development, the research and development of chemical drugs is becoming more and more complicated and lengthy. The disciplines involved are not only chemistry, but also biology, medicine, information science (computer-aided), materials science and other knowledge.

At present, it takes an average of 12 years for a new drug to go from initial laboratory research to marketing.

According to the statistics of the World Health Organization, only 5000 of the 5 compounds undergoing preclinical trials can enter the follow-up clinical trials.

Only one of these compounds was finally approved for marketing.

A complete set of new compound R&D cycle takes more than 10 years and costs billions of dollars on average. It is normal for international pharmaceutical giants or large CROs to have more than [-] professionals in their research and testing teams for a single compound. The process is extremely cumbersome and complicated.

Shen Qi can only do the stage of synthesizing samples and animal experiments in the laboratory, and his center is temporarily not qualified to complete a full set of drug research and development, testing, and improvement work: "I decided to sell the patent of C01B."

Director Qi reminded: "The bid from the Americans will not be too high."

Shen Qi nodded and said: "Understood, my C01B has not undergone any experiments, not even animal experiments. Since Green Mountain Pharmaceuticals dares to buy, then I dare to sell."

Compounds undergoing preclinical testing can enter the clinical phase I, that is, to test whether the compound has toxicity or other dangerous side effects on normal healthy people. This promotion rate is only one in a thousand.

After clinical phase I, there are II~IV, and the uncertainty is too high.

The C01B synthesized by Shen Qi and Lao Yan has not even been tested on animals, let alone clinical.

Whether or not C01B has practical value will not be determined until many years later.

At this stage, someone dares to buy the laboratory compound C01B, which requires a strong predictive power, and there is also an element of gambling.

Drug development is an industry full of drama.

In 1968, the new drug research and development team of Regan Corporation in the United States successfully synthesized a new compound, sevoflurane, in experiments. They observed that sevoflurane decomposition products had certain nephrotoxicity in a high temperature test at 210 degrees Celsius.

As a result, researchers in the United States believed that sevoflurane had no future, and sold its patent to Maruishi Corporation in Japan at a very low price.

Maruishi Company is secretly happy, and they feel like they have found a treasure.

After optimization and improvement, Maruishi launched an improved version of sevoflurane in 1993, which was first listed in Japan under the trade name Ultane.

In nearly 200 million clinical observations, sevoflurane has shown excellent efficacy and safety, and it has been marketed in dozens of countries including China, the United States, and South Korea.

The Chinese product name of sevoflurane is Kaili, which is an inhaled general anesthetic. Many hospitals in China use Kaili when operating on patients.

Compounds that have no future in the eyes of American researchers have become treasures in the hands of Japanese pharmacists. This is the drama of the drug development industry.

Of course, the cycle of turning waste into treasure is quite long. It took Maruishi a full 25 years to make sevoflurane an excellent anesthetic recognized by the medical community.

Let alone 25 years, Shen Qi doesn't even want to wait for 5 years. His purpose of entering the chemical industry is not to develop smoking cessation drugs. C01B is just a windfall: "Then please ask Director Qi, I mean C01B can be sold, the patent transfer price On the one hand, Director Qi will follow the rules and talk to the other party."

Just as the old saying goes, mathematics and physics are the fires that start a prairie fire and the lights that point the way, and chemistry and biology are the crematorium and the pit for burying science students.

Shen Qi lit the fire and lit the lamp.

Now that Shen Qi has fallen into the pit, this is the fate of science students.

Playing with biochemistry is really a very complicated project, Shen Qi is most comfortable with mathematics, physics and politics.

Because of Director Qi's temporary visit, Shen Qi only wrote an extra article on condensed matter physics before leaving get off work at 5 o'clock.

"Today I will work overtime, and I will be home before 10 o'clock." Shen Qi sent a message to Ouye, and he wanted to finish the other two physics extra chapters in one go.

There are a total of four episodes on Mathematics and Physics. If they are all published, Shen Qi predicts that they will be able to save enough points for Mathematics to advance to level 15.

Ouye replied to the message: "Go home and eat first, then go to work after eating."

Academician Shen's villa is very close to Yanda University, and it only takes 10 minutes to walk.

The wife is the biggest in heaven and earth, and the wife ordered to go home for dinner, so Shen Qi must go home for dinner.

Shen Qi went home to eat, after the meal, teased the baby, and even worked overtime, he didn't want to work overtime anymore.

The next day, Shen Qi finished writing all the extra articles, sent them to relevant mathematics and physics journals, and then reviewed the documents that needed his confirmation.

The reason why the leader of a scientific research institution or scientific research team is called a boss is because the bosses are busy with business and there are many documents that need to be handled by the boss.

Especially if he is a boss at the top level, his signature may involve tens of millions or even hundreds of millions of scientific research funds.

All scientific researchers with the title of associate professor or above in the center are eligible to apply for scientific research projects individually.

After receiving the training from the principal of the party school, Shen Qi was very cautious about applying for large amounts of scientific research funding.

It doesn't matter if the project is less than 100 million, Shen Qi approved it without any hassle.

Shen Qi must strictly control the theoretical research projects with more than 100 million yuan and the applied projects with more than 1 million yuan.

Associate Professor Xiao Junlong submitted an application for a mathematics project, the application fund was 98 RMB, and the list was detailed and clear.

"Is it stuck, Lao Xiao, you have studied me very thoroughly." Shen Qi's hand holding the pen did not sign for a long time, and all the people under him have become masters.

(End of this chapter)